The Weight of Failure: Novo Nordisk's Rocky Road Ahead Novo Nordisk's meteoric rise as Europe's most valuable company has been marked by the blockbuster success of its weight loss drugs, particularly Ozempic and Wegovy.
However, the Danish pharmaceutical giant's struggles to replicate this magic have been well documented.
The recent failure of ziltivekimab in phase III trials has brought Novo Nordisk's long term growth prospects into sharp focus.